Achillion Pharma Out-Licensed China Rights for HIV, Hepatitis Treatment

Prohost Biotech submits: When the human immunodeficiency virus (HIV) was identified as the cause of the mysterious immune system depletion characterized by horrific vulnerability to infection, multiple dreadful symptoms and ultimately death, the world panicked. The medical and research communities were taken by surprise. Nothing could be said or done to help the agonizing victims or prevent their imminent death.

ByPropThink:By Jake KingAchillion

The US Food and Drug Administration on Friday approved a new drug, Edurant, to fight HIV in combination with other antiretrovirals already on the market.Made by the New Jersey based Tibotec Therapeutics, Edurant helps block the virus from replicating and is part of a class of drugs known as non-nucleoside reverse transcriptase inhibitor.The pill is to be taken once daily with food, the FDA said.

By Matt Schilling:There is no doubt Hepatitis C is one of the deadliest and most painful diseases any one can endure, and in an effort to fight back against its deadly wrath, Achillion Pharmaceuticals (ACHN) is making considerable strides in terms of four drugs currently in its pipeline.

Hundreds of patients of an Oklahoma oral surgeon accused of unsanitary practices showed up at a health clinic Saturday, looking to find out whether they were exposed to hepatitis or the virus that causes AIDS.

Researchers believe that there will be a breakthrough in finding a cure for HIV “within months”. Danish scientists are expecting results that will show that “finding a mass-distributable and affordable cure to HIV is possible”.

ChinaBio Today submits: Two Japanese drug companies, Teijin Pharma (TINLF.PK) and Astellas (ALPMF.PK)

ChinaBio Today submits: 3SBio Inc. (NSDQ: SSRX) in-licensed the China rights to voclosporin, a calcineurin inhibitor, from Isotechnika Pharma Inc. [TSX: ISA], a Canadian biopharma.